Home › NDC Lookup › RxCUI directory › RxCUI 2102784

Revefenacin 0.0583 MG/ML Inhalation Solution [Yupelri] — RxCUI 2102784

Name: Revefenacin 0.0583 MG/ML Inhalation Solution [Yupelri] (RxCUI 2102784)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2102784 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2102784

Official nameRevefenacin 0.0583 MG/ML Inhalation Solution [Yupelri]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asYupelri 0.0583 MG/ML Inhalation Solution; YUPELRI 175 MCG in 3 ML Inhalation Solution; Yuperlri 175 MCG per 3 ML Inhalation Solution

FDA products mapped1

Package NDCs mapped2

Reported Medicaid activity (SDUD)20,174 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Revefenacin Oral Inhalation: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Yupelri is a maintenance medicine — you use it every single day to keep your airways open and make day-to-day breathing easier with COPD. It is not a rescue inhaler. If you're havi...
What exactly is Yupelri for, and will it help me during a flare-up?
You open the single-dose vial right before your treatment — not ahead of time — and pour the liquid into a standard jet nebulizer connected to an air compressor. You breathe the mi...
The most common side effects are pretty mild — cough, cold-like symptoms, headache, and back pain. Some people notice dry mouth over time. What you really want to watch for are war...

📖 Read our full Revefenacin Oral Inhalation guide →

🕸️ Concept Web — How Revefenacin 0.0583 MG/ML Inhalation Solution [Yu... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Revefenacin 0.0583 MG/ML Inhalation Solution [Yupelri] RxCUI 2102784 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Revefenacin 2102775 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Yupelri 2102780 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Revefenacin Inhalation Solution 2108378 SCDF
- Revefenacin Inhalant Product 2102777 SCDG
- Revefenacin Inhalation Solution [Yupelri] 2108380 SBDF
- Yupelri Inhalant Product 2102783 SBDG
- Inhalation Solution 346161 DF
- Inhalant Product 1151123 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Revefenacin 0.0583 MG/ML Inhalation Solution 2102779 SCD
- Revefenacin 0.0583 MG/ML 2102776 SCDC
- Revefenacin 0.0583 MG/ML [Yupelri] 2102781 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Revefenacin 0.0583 MG/ML Inhalation Solution SCD · 2102779
Revefenacin 0.0583 MG/ML SCDC · 2102776
Revefenacin Inhalation Solution SCDF · 2108378
Revefenacin Inhalant Product SCDG · 2102777

Brand-Name Concepts

Revefenacin 0.0583 MG/ML [Yupelri] SBDC · 2102781
Revefenacin Inhalation Solution [Yupelri] SBDF · 2108380
Yupelri Inhalant Product SBDG · 2102783
Yupelri BN · 2102780

📦 FDA Products & Package NDCs

1 product · 2 package NDCs

2 package NDCs map to RxCUI 2102784 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
49502-0806-87	7 POUCH in 1 CARTON (49502-806-87) / 1 VIAL, SINGLE-DOSE in...	YUPELRI	Viatris Specialty LLC	2019-01-01
49502-0806-93	30 POUCH in 1 CARTON (49502-806-93) / 1 VIAL, SINGLE-DOSE i...	YUPELRI	Viatris Specialty LLC	2018-12-03

Observed labelers: Viatris Specialty LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$17.4825

Range $17.4825–$17.4825 · middle 50% $17.4825–$17.4825 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J7677	Revefenacin inh non-com 1mcg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.